Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000162 | 0.94 | SMN1; SMN2 (0.68) | SMN1; SMN2USP2TSHRL3MBTL1RECQL | |
| SCHEMBL24693743 | 0.81 | MEN1 (0.52) | SMN1; SMN2USP2MEN1KMT2AHPGD | |
| SCHEMBL1487171 | 0.81 | MEN1 (0.49) | SMN1; SMN2USP2MEN1KMT2AHPGD | |
| SCHEMBL189729 | 0.81 | MEN1 (0.49) | SMN1; SMN2USP2MEN1KMT2AALDH1A1 | |
| SCHEMBL3086430 | 0.81 | USP2 (0.75) | SMN1; SMN2USP2TSHRRECQLMEN1 | |
| SCHEMBL6963497 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2USP2TSHRL3MBTL1RECQL | |
| SCHEMBL24762569 | 0.80 | USP2 (0.73) | SMN1; SMN2USP2TSHRRECQLMEN1 | |
| SCHEMBL2920417 | 0.79 | SMN1; SMN2 (0.83) | SMN1; SMN2USP2TSHRRECQLMEN1 | |
| SCHEMBL12629406 | 0.78 | USP2 (0.76) | SMN1; SMN2USP2TSHRRECQLMEN1 | |
| SCHEMBL344191 | 0.78 | SMN1; SMN2 (0.96) | SMN1; SMN2USP2TSHRRECQLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC | 2004-02-19 | — | — | US | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6649620-B2 | Particularly in the treatment of benign prostatic hyperplasia. | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030045525-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2003-03-06 | — | — | US | disclosed |
| EP-0875506-B1 | Quinoline and quinazoline compounds useful in therapy | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
| EP-0875506-A1 | Quinoline and quinazoline compounds useful in therapy | Pfizer Limited (GB) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045525-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, BPHL | SMN1; SMN2 3252/4885USP2 3346/4885TSHR 1730/4885 |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | SMN1; SMN2 3821/4885USP2 3379/4885TSHR 2135/4885 |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, SDHA | SMN1; SMN2 3191/4885USP2 3480/4885TSHR 1799/4885 |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | SMN1; SMN2 3839/4885USP2 3351/4885TSHR 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.